NeuroOne Medical Technologies Corporation — Cyborg Score 5/10
Solid
Neuromodulation and neurosurgical devices
Strategic Profile
NeuroOne is a developmental stage company committed to providing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions. Q2 FY2026 saw 72% YoY product revenue growth to $2.4M, driven by OneRF Brain Ablation sales and strong clinical adoption, with FY2026 guidance of $10.5M and international expansion and drug delivery commercialization targeted for late 2026.
Cyborg Score Rationale
FY2025 revenue was $12.10 million, an increase of 250.35% from prior year, with losses of -$3.61 million, 70.73% less than 2024. The company demonstrates strong revenue acceleration and commercial traction, but remains in early commercialization with small revenue scale and ongoing operating losses. Market valuation appears significantly discounted relative to growth trajectory.
Top Insights
Q2 2026 showed 72% YoY product revenue growth driven by OneRF Brain Ablation sales and strong clinical adoption
NeuroOne's ablation system launched in US earlier than expected, suggesting accelerated market penetration
International expansion and drug delivery commercialization targeted for late 2026, representing significant growth catalysts
The company has a collaboration with the Department of Neurology's Division of Epilepsy at the University of Minnesota Medical School, enhancing clinical credibility
Named Competitors
Deep Brain Stimulation (DBS) Systems — Leading neuromodulation and DBS device manufacturer
Boston Scientific Neuromodulation — Major player in neuromodulation and spinal devices
Abbott NeuroModulation — Diversified healthcare company with neuromodulation portfolio
Neuropathix Electrode Systems — Competitor in electrode recording and monitoring systems
Recent Developments
(May 2026) Q2 FY2026 earnings released showing 72% YoY revenue growth to $2.4M with OneRF system driving strong clinical adoption
(February 2026) Q1 2026 earnings reported with guidance of at least $10.5M for fiscal 2026
(September 2025) FDA clearance received for OneRF Trigeminal Nerve Ablation System, expanding treatment indications
Open the full interactive NeuroOne Medical Technologies Corporation report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.